Targeted Therapy, Immune Cell, and Bispecific Antibody Basics
Key Takeaways
- Targeted therapies act on cancer-associated pathways or markers and require attention to biomarker testing, administration route, adherence, interactions, and unique toxicities.
- Monoclonal antibodies, antibody drug conjugates, tyrosine kinase inhibitors, proteasome inhibitors, PARP inhibitors, and mTOR or CDK inhibitors have different monitoring needs.
- CAR T-cell therapy and other immune cell therapies can cause cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
- Bispecific antibodies can redirect immune cells toward cancer cells and may require step-up dosing, observation, infection precautions, and urgent escalation for CRS or neurologic changes.
- RN education focuses on symptom reporting, infection prevention, medication adherence, reproductive precautions, and when to seek emergency care.
Targeted Therapy, Immune Cell, and Bispecific Antibody Basics
Targeted therapy refers to cancer treatment designed around a molecular pathway, cell surface antigen, growth signal, repair defect, or tumor microenvironment feature. These agents may be given orally, subcutaneously, or intravenously and are often paired with biomarker testing. The RN does not interpret genomic results independently, but should understand why a marker matters, whether the patient has access to the drug, and what monitoring is expected.
Major Targeted Therapy Groups
Small-molecule inhibitors often end in -ib and may target kinases, proteasomes, PARP repair pathways, BCL-2, mTOR, or other signaling systems. Monoclonal antibodies often end in -mab and bind cell surface targets or immune pathways. Antibody drug conjugates combine an antibody with a cytotoxic payload; they require both antibody-related reaction monitoring and payload-specific toxicity awareness. Some therapies are continuous oral medications, making adherence, food requirements, drug interactions, and safe storage central nursing issues.
| Therapy type | RN monitoring emphasis |
|---|---|
| Tyrosine kinase inhibitor | Blood pressure, diarrhea, rash, liver tests, cardiac symptoms, interactions |
| Antibody drug conjugate | Infusion reaction, neuropathy, cytopenias, lung or eye toxicity when applicable |
| PARP inhibitor | Fatigue, nausea, cytopenias, adherence, reproductive precautions |
| Proteasome inhibitor | Neuropathy, infection risk, thrombocytopenia, herpes zoster prophylaxis if ordered |
| Monoclonal antibody | Infusion reaction, target-specific effects, infection risk |
Immune Cell Therapies
CAR T-cell therapy and related immune effector cell therapies collect or use immune cells that are engineered or selected to attack cancer. Care occurs across phases: referral, cell collection, bridging therapy, lymphodepleting treatment, infusion, monitoring, and long-term follow-up. Two hallmark toxicities are cytokine release syndrome, or CRS, and immune effector cell-associated neurotoxicity syndrome, or ICANS. CRS may include fever, hypotension, hypoxia, tachycardia, rigors, and organ dysfunction. ICANS may include confusion, aphasia, tremor, handwriting change, seizure, somnolence, or cerebral edema.
Bispecific Antibodies
Bispecific antibodies bind two targets, commonly one on an immune cell and one on a cancer cell. By bringing immune cells close to malignant cells, these drugs can cause immune activation similar to cellular therapy, including CRS and neurologic toxicity. Many products use step-up dosing, premedication, inpatient or outpatient observation, and strict instructions for when to return urgently. The RN should verify the patient understands that fever after therapy is not routine until assessed, especially during early cycles.
Naming and Mechanism Clues
Generic drug names can provide clues. The suffix -mab suggests a monoclonal antibody, -nib suggests a kinase inhibitor, -zomib suggests a proteasome inhibitor, -parib suggests a PARP inhibitor, and -ciclib suggests a CDK inhibitor. These suffixes are not enough for independent clinical decisions, but they help the nurse anticipate route, reaction risk, oral adherence needs, and education themes. Brand names should not replace generic names in teaching because patients may encounter either in portals, pharmacy labels, and emergency records.
Nursing Safety Priorities
Targeted therapy toxicity may be subtle at first. Assess for hypertension, rash, diarrhea, edema, dyspnea, cough, neuropathy, vision changes, infection, bleeding, fatigue, mood changes, and adherence barriers. For oral agents, review missed-dose instructions from the prescription label or clinic policy without inventing new directions. Check for supplements, grapefruit products, acid-suppressing therapy, anticoagulants, anticonvulsants, and other interaction risks when relevant and route concerns to the pharmacist or provider.
Practice Priorities
The phrase targeted therapy can falsely suggest low risk. Many agents are highly specific in mechanism but broad in clinical consequences. A rash may predict activity for some drugs yet still require management; diarrhea can become severe; hypertension can become dangerous; and lung symptoms may signal drug-related pneumonitis. Nurses should teach patients the generic name, the target if known in plain language, and the symptoms that cannot wait. For cellular and bispecific therapies, fever plus dizziness, oxygen need, or neurologic change should be treated as urgent until evaluated.
- Link the drug name to mechanism and likely monitoring.
- Escalate fever after immune cell therapy or bispecific antibody treatment.
- Treat new confusion or speech change as urgent.
- Reinforce that oral targeted therapy is hazardous medication and requires safe handling.
Which finding after CAR T-cell therapy should the nurse escalate urgently?
What does the generic suffix -mab most commonly suggest?
A patient receiving an early-cycle bispecific antibody calls with fever and dizziness. What is the best advice within RN triage scope?